NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?

Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression

(2017) Massimo Giuliani et al.   Oncotarget

Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation

(2016) Brian C. Shaffer et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation

(2016) Rohtesh S. Mehta et al.   BRITISH JOURNAL OF HAEMATOLOGY

Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment

(2016) Jeremiah L. Oyer et al.   CYTOTHERAPY

Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival

(2016) Sarah Oelsner et al.   INTERNATIONAL JOURNAL OF CANCER

Enhanced Cytotoxic Function of Natural Killer and CD3+CD56+ Cells in Cord Blood after Culture

(2015) Suzanne L. Tomchuck et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach

(2015) Jeremiah L. Oyer et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

(2015) A. Rothe et al.   BLOOD

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma

(2015) Congcong Zhang et al.   JNCI-Journal of the National Cancer Institute

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer

(2015) David L. Hermanson et al.   STEM CELLS

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma

(2015) Congcong Zhang et al.   JNCI-Journal of the National Cancer Institute

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma

(2014) Jessica Rueff et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

(2013) H. E. Kohrt et al.   BLOOD

Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells

(2012) Cecele J. Denman et al.   PLoS One

Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow Transplantation

(2012) Leo Luznik et al.   SEMINARS IN ONCOLOGY

Natural killer cells: a review of manufacturing and clinical utility

(2012) Scott A. Koepsell et al.   TRANSFUSION

Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function

(2011) Prakash Satwani et al.   CYTOTHERAPY

Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation

(2010) Stefan O. Ciurea et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared with One Human Leukocyte Antigen Mismatched Related Donors Using HLA Typing at 10 Loci

(2010) Stefan O. Ciurea et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer

(2010) Teemu T. Junttila et al.   CANCER RESEARCH

Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas

(2010) Luis F. Porrata et al.   Clinical & Developmental Immunology

Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation

(2009) Heather J. Symons et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

(2009) Andrés López-Albaitero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

(2009) Maria Berg et al.   CYTOTHERAPY

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

(2008) E. Alici et al.   BLOOD

The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease

(2008) E. M. Dunbar et al.   HAEMATOLOGICA

Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation

(2008) Sandrine Meyer-Monard et al.   TRANSFUSION